Through this strategic partnership, Rousselot and TIBI will collaborate on the development of gelatin-based therapies and their translation to the clinic. Rousselot will supply TIBI with X-Pure® modified gelatins such as X-Pure GelMA, while exchanging insights on the behavior of gelatin in the institute's research and clinical trials.
With more than 130 years of gelatin and collagen expertise, Rousselot created X-Pure®, a full range of biomedical gelatins and modified gelatins, characterized by their unmatched purity (<10EU/g endotoxin) and consistency, as well as full compliance with GMP. Part of this range, Rousselot’s X-Pure® GelMA modified gelatins have already been tested and recognized for their premium quality by TIBI’s researchers.
“We are excited to partner with Rousselot and to be able to use Rousselot’s modified gelatins for our research”, explains Ali Khademhosseini, CEO of TIBI. “Modified gelatins have proven to be powerful biomaterials in the regenerative medicine field, and we have been using them heavily over the past few years. I am certain that high-quality, purified GelMA will support both our in vitro and in vivo research and development. With X-Pure GelMA, we will be able to make further strides in the clinical translation of our research to accelerate the development of new therapies.”
“We are delighted to work together with TIBI and its team of world-renowned researchers”, said Jos Vervoort, Rousselot’s Executive Vice-President. “X-Pure® modified gelatins are low-endotoxin, batch-to -batch consistent and GMP ready, making them suitable for research and clinical translation. Their purity and scalability will support the full cycle of research and clinical development and we are proud to play a role in helping the experts at TIBI translate their research into viable biomedical solutions that can help patients across the planet.”
The Partnership is effective from January 1st, 2022 and will have an initial duration of two years, fostering a close collaboration between TIBI’s experts on microneedles and 3D-bioprinting and Rousselot’s experts in collagen- and gelatin-based biomaterials.